JP2003506077A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003506077A5 JP2003506077A5 JP2001515808A JP2001515808A JP2003506077A5 JP 2003506077 A5 JP2003506077 A5 JP 2003506077A5 JP 2001515808 A JP2001515808 A JP 2001515808A JP 2001515808 A JP2001515808 A JP 2001515808A JP 2003506077 A5 JP2003506077 A5 JP 2003506077A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- serum
- cells
- protein
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 description 101
- 210000002966 serum Anatomy 0.000 description 31
- 239000002609 medium Substances 0.000 description 30
- 238000004113 cell culture Methods 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 27
- 239000000047 product Substances 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 17
- 238000000034 method Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 10
- 238000013411 master cell bank Methods 0.000 description 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
- 239000000654 additive Substances 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 239000002028 Biomass Substances 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 229960000182 blood factors Drugs 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108010054218 Factor VIII Proteins 0.000 description 3
- 102000001690 Factor VIII Human genes 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229960000301 factor viii Drugs 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GKWTZACONBQTNK-IVIZKJKWSA-N N-benzyl-7H-purin-6-amine (1R,2R,5R,8R,9S,10R,12S)-12-hydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadecane-9-carboxylic acid (1R,2R,5R,8R,9S,10R,12S)-12-hydroxy-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadec-13-ene-9-carboxylic acid Chemical compound C(Nc1ncnc2nc[nH]c12)c1ccccc1.CC12[C@H]3[C@H](C(O)=O)[C@@]45C[C@@H](CC[C@H]4[C@@]3(CC[C@@H]1O)OC2=O)C(=C)C5.CC12[C@H]3[C@H](C(O)=O)[C@@]45C[C@@H](CC[C@H]4[C@]3(OC1=O)C=C[C@@H]2O)C(=C)C5 GKWTZACONBQTNK-IVIZKJKWSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/AT1999/000197 WO2001011021A1 (de) | 1999-08-05 | 1999-08-05 | Rekombinanter stabiler zellklon, seine herstellung und verwendung |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010024874A Division JP2010099093A (ja) | 2010-02-05 | 2010-02-05 | 組換え安定細胞クローン、その産生およびその使用 |
| JP2010176423A Division JP2011004754A (ja) | 2010-08-05 | 2010-08-05 | 組換え安定細胞クローン、その産生およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003506077A JP2003506077A (ja) | 2003-02-18 |
| JP2003506077A5 true JP2003506077A5 (https=) | 2010-09-30 |
Family
ID=3683861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001515808A Withdrawn JP2003506077A (ja) | 1999-08-05 | 1999-08-05 | 組換え安定細胞クローン、その産生およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1200561B1 (https=) |
| JP (1) | JP2003506077A (https=) |
| AT (1) | ATE330003T1 (https=) |
| AU (1) | AU780810B2 (https=) |
| CA (1) | CA2381173A1 (https=) |
| CY (1) | CY1106111T1 (https=) |
| DE (1) | DE59913565D1 (https=) |
| DK (1) | DK1200561T3 (https=) |
| ES (1) | ES2267280T3 (https=) |
| PT (1) | PT1200561E (https=) |
| WO (1) | WO2001011021A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1482031B1 (en) | 1996-08-30 | 2015-10-28 | Life Technologies Corporation | Serum-free mammalian cell culture medium, and uses thereof |
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| EP1325127B1 (en) * | 2000-10-02 | 2009-03-11 | Novo Nordisk Health Care AG | Method for the production of vitamin k-dependent proteins |
| EP1434857B1 (en) | 2001-10-02 | 2007-08-01 | Novo Nordisk Health Care AG | Method for production of recombinant proteins in eukaryote cells |
| HUP0402226A2 (hu) * | 2001-11-28 | 2005-02-28 | Sandoz Ag. | Eljárás sejttenyésztésre |
| WO2003048357A1 (fr) * | 2001-12-04 | 2003-06-12 | Mitsubishi Pharma Corporation | Procede d'activation de proteine |
| PT2287288E (pt) | 2002-07-09 | 2012-12-10 | Baxter Int | Meio isento de proteína animal para cultura de células |
| DE10338531A1 (de) * | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| US8669109B2 (en) | 2003-08-19 | 2014-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methods of producing proteins in Chinese hamster ovary (CHO) cells |
| JP2008504008A (ja) * | 2003-12-31 | 2008-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質 |
| US20060094104A1 (en) * | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| AU2011221414B2 (en) * | 2004-10-29 | 2012-09-20 | Takeda Pharmaceutical Company Limited | Animal Protein-Free Media for Cultivation of Cells |
| ATE541919T1 (de) | 2005-02-11 | 2012-02-15 | Novo Nordisk Healthcare Ag | Herstellung eines proteins in serumfreier zellkultur, die ein proteinhydrolysat aus pflanzen enthält |
| EP3653699A1 (en) | 2006-01-04 | 2020-05-20 | Baxalta Incorporated | Oligopeptide-free cell culture media |
| CA2742107A1 (en) | 2008-11-12 | 2010-05-20 | Baxter International Inc. | Method of producing serum-free insulin-free factor vii |
| WO2024024671A1 (ja) * | 2022-07-27 | 2024-02-01 | 不二製油グループ本社株式会社 | 動物細胞増殖促進剤 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022545D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| DE4313620A1 (de) * | 1993-04-26 | 1994-10-27 | Biotechnolog Forschung Gmbh | Hamsterzellinien und Verfahren zur Glykoproteingewinnung |
| EP0666312A1 (en) * | 1994-02-08 | 1995-08-09 | Wolfgang A. Renner | Process for the improvement of mammalian cell growth |
| ES2378409T3 (es) * | 1994-11-10 | 2012-04-12 | Baxter Healthcare S.A. | Método para producir sustancias biológicas en cultivo sin proteínas |
| EP0799310A1 (en) * | 1994-12-16 | 1997-10-08 | Novartis AG | Production of recombinant secretory component |
| AUPN442295A0 (en) * | 1995-07-26 | 1995-08-17 | Commonwealth Scientific And Industrial Research Organisation | Regulated autocrine growth of mammalian cells |
| US5851800A (en) * | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
-
1999
- 1999-08-05 AT AT99939251T patent/ATE330003T1/de active
- 1999-08-05 DE DE59913565T patent/DE59913565D1/de not_active Expired - Lifetime
- 1999-08-05 CA CA 2381173 patent/CA2381173A1/en not_active Abandoned
- 1999-08-05 AU AU53636/99A patent/AU780810B2/en not_active Expired
- 1999-08-05 EP EP99939251A patent/EP1200561B1/de not_active Revoked
- 1999-08-05 WO PCT/AT1999/000197 patent/WO2001011021A1/de not_active Ceased
- 1999-08-05 PT PT99939251T patent/PT1200561E/pt unknown
- 1999-08-05 DK DK99939251T patent/DK1200561T3/da active
- 1999-08-05 ES ES99939251T patent/ES2267280T3/es not_active Expired - Lifetime
- 1999-08-05 JP JP2001515808A patent/JP2003506077A/ja not_active Withdrawn
-
2006
- 2006-07-03 CY CY20061100911T patent/CY1106111T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6100061A (en) | Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone | |
| JP2003506077A5 (https=) | ||
| US7094574B2 (en) | Recombinant cell clones having increased stability and methods of making and using the same | |
| JP5441288B2 (ja) | 細胞の無タンパク質かつ無血清の培養のための培地 | |
| Darlington | [3] Liver cell lines | |
| JP2003506077A (ja) | 組換え安定細胞クローン、その産生およびその使用 | |
| JP2525436B2 (ja) | 細胞培養による蛋白質の製造 | |
| JP4478328B2 (ja) | 生化学的薬剤の生産のための細胞の調製 | |
| JP6245299B2 (ja) | 組換え安定細胞クローン、その産生およびその使用 | |
| JP6097725B2 (ja) | 組換え安定細胞クローン、その産生およびその使用 | |
| JP2011004754A (ja) | 組換え安定細胞クローン、その産生およびその使用 | |
| JP2010099093A (ja) | 組換え安定細胞クローン、その産生およびその使用 | |
| JPH05207874A (ja) | 無血清培地 | |
| JPH05207875A (ja) | 無血清培地 | |
| JPS61271987A (ja) | ウロキナ−ゼ前駆体の製造方法 |